Pacific Biosciences of California (NASDAQ:PACB) Given "Neutral" Rating at Piper Sandler

Pacific Biosciences of California logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Piper Sandler reaffirmed its Neutral rating on Pacific Biosciences and raised its price target from $2 to $3, implying 18.34% upside from the prior close.
  • Analyst sentiment is mixed: PACB has an average “Reduce” rating and a consensus price target of $1.96, with one Buy, three Hold, and two Sell ratings.
  • PacBio’s latest quarter beat expectations, reporting a loss of $0.11 per share and $40.56 million in revenue. The company narrowed its 2026 revenue outlook to $155 million–$160 million and is targeting cash-flow breakeven in 2028.
  • MarketBeat previews top five stocks to own in December.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report)'s stock had its "neutral" rating reissued by equities researchers at Piper Sandler in a research note issued to investors on Thursday, Benzinga reports. They currently have a $3.00 price target on the biotechnology company's stock, up from their previous price target of $2.00. Piper Sandler's price objective suggests a potential upside of 18.34% from the stock's previous close.

Several other equities research analysts have also recently weighed in on PACB. UBS Group began coverage on Pacific Biosciences of California in a research note on Wednesday, September 9th. They set a "neutral" rating and a $1.35 target price for the company. Wall Street Zen cut Pacific Biosciences of California from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings raised shares of Pacific Biosciences of California from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, October 13th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Pacific Biosciences of California currently has an average rating of "Reduce" and an average price target of $1.96.

Get Our Latest Research Report on PACB

Pacific Biosciences of California Stock Down 0.6%

Shares of NASDAQ PACB traded down $0.01 during midday trading on Thursday, hitting $2.54. The stock had a trading volume of 11,658,444 shares, compared to its average volume of 8,296,380. The company has a market capitalization of $787.95 million, a PE ratio of -5.92 and a beta of 2.21. Pacific Biosciences of California has a 1 year low of $1.07 and a 1 year high of $3.43. The stock has a 50 day simple moving average of $1.89 and a 200-day simple moving average of $1.62.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. Pacific Biosciences of California had a negative return on equity of 5,752.12% and a negative net margin of 82.49%. The firm had revenue of $40.56 million for the quarter, compared to analysts' expectations of $39.31 million. As a group, analysts expect that Pacific Biosciences of California will post -0.52 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Mark Van Oene sold 26,911 shares of Pacific Biosciences of California stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1.13, for a total value of $30,409.43. Following the completion of the transaction, the insider directly owned 2,705,853 shares of the company's stock, valued at approximately $3,057,613.89. The trade was a 0.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James R. Gibson II sold 661,815 shares of the company's stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total value of $2,058,244.65. Following the transaction, the insider directly owned 1,083,848 shares of the company's stock, valued at $3,370,767.28. This trade represents a 37.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is owned by company insiders.

Institutional Trading of Pacific Biosciences of California

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Essential Partners LLC bought a new position in Pacific Biosciences of California during the 1st quarter valued at $25,000. Choreo LLC purchased a new position in Pacific Biosciences of California during the 3rd quarter worth approximately $27,000. Interchange Capital Partners LLC acquired a new position in Pacific Biosciences of California during the third quarter valued at $28,000. Corient Private Wealth LP purchased a new stake in shares of Pacific Biosciences of California in the second quarter worth approximately $30,000. Finally, Pinegrove Venture Partners LLC purchased a new position in shares of Pacific Biosciences of California during the 2nd quarter valued at $34,584.

Key Pacific Biosciences of California News

Here are the key news stories impacting Pacific Biosciences of California this week:

  • Positive Sentiment: For Q3 2026, PacBio reported a loss of $0.11 per share, better than the $0.13 loss analysts expected, while revenue of $40.56 million exceeded the $39.31 million consensus estimate. Zacks Q3 earnings report
  • Positive Sentiment: A Q3 analysis pointed to clinical adoption and AI partnerships as contributors to steady growth, suggesting potential longer-term demand opportunities. Q3 clinical adoption and AI partnerships analysis
  • Neutral Sentiment: PacBio narrowed its 2026 revenue guidance to $155 million–$160 million. A tighter range provides an updated outlook, but the article does not specify whether it represents a change in expected performance. Revenue guidance and cash-flow target
  • Negative Sentiment: The company still posted a quarterly loss, and management is targeting cash-flow breakeven only in 2028, underscoring the time and execution required to reach sustainable finances. Cash-flow breakeven outlook

About Pacific Biosciences of California

(Get Free Report)

Pacific Biosciences of California, Inc NASDAQ: PACB is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio's product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.

Read More

Analyst Recommendations for Pacific Biosciences of California (NASDAQ:PACB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pacific Biosciences of California Right Now?

Before you consider Pacific Biosciences of California, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacific Biosciences of California wasn't on the list.

While Pacific Biosciences of California currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines